Le Lézard
Classified in: Health
Subjects: PDT, FDA

Beckman Coulter Diagnostics Expands Chemistry Menu to include FDA-cleared Procalcitonin (PCT)



BREA, Calif., June 21, 2017 /PRNewswire/ -- Beckman Coulter Diagnostics along with partner Diazyme Laboratories announces FDA clearance of a new procalcitonin (PCT) assay, an important tool for the management of bacterial infections and sepsis.

Beckman Coulter logo. (PRNewsFoto/Beckman Coulter, Inc.)

Sepsis is the leading cause of death in U.S. hospitals, according to the Sepsis Alliance. More than 1.6 million people in the U.S. are diagnosed with sepsis annually. Sepsis is the number one cost of hospitalization in the U.S. consuming more than $24 billion each year as well as ranking as the top cause for readmissions to the hospital.

"Fast diagnosis and treatment are critical for patients who have become septic," said Mike Samoszuk, M.D., vice president and chief medical officer at Beckman Coulter Diagnostics. "Adding PCT to our chemistry menu offers a tool for managing bacterial infections and sepsis, which should, inform the course and prognosis of the disease and facilitate therapeutic decisions. This addition is a result of our commitment to providing disease-state-management solutions."

This assay is the first homogenous PCT assay for use on current Beckman Coulter AU model chemistry analyzers eliminating the need for costly dedicated instrumentation. The assay features a latex-enhanced immunoturbidimetric methodology, which uses multiple monoclonal antibodies for enhanced assay sensitivity and specificity. The high-quality, fully automated PCT assay is available for use with Beckman Coulter AU analyzers, models 480, 680 and 5800. 

"Healthcare providers face challenges in timely diagnosis of bacterial infections and sepsis," said Jack Zakowski, PhD, FACB, director, scientific affairs at Beckman Coulter. "Our AU analyzers are known for high performance, speed and accuracy. Combining our chemistry systems with this PCT assay results in fast turnaround times, and enables rapid assessment of patients in these critical situations."

Beckman Coulter has partnered with Diazyme Laboratories to distribute the PCT assay to ensure delivery of the broadest range of solutions for clinical laboratories. Diazyme Laboratories is a cGMP and ISO 13485 certified medical device manufacturer, utilizing proprietary enzyme and immunoassay technologies to develop diagnostic reagents in user-friendly formats.

About Beckman Coulter

Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering the accurate diagnostic information they need, when they need it. For over 80 years, Beckman Coulter has been the partner of choice for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers' mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit and we can move healthcare forward for every person.

Beckman Coulter, the stylized logo and the Beckman Coulter product and service marks mentioned herein are trademarks or registered trademarks of Beckman Coulter, Inc. in the United States and other countries.

 

SOURCE Beckman Coulter Diagnostics


These press releases may also interest you

at 15:58
RACINE, Wis., Oct. 17, 2017 /PRNewswire/ -- SC Johnson today announced the donation of $100,000 to the Red Cross to help relief efforts following the earthquakes and aftershocks that devastated parts of Mexico. "Our...

at 15:57
NEW YORK, Oct. 17, 2017 /PRNewswire/ -- "Increasing demands for water & wastewater treatment are fueling the Polyvinylidene Difluoride (PVDF) membrane market"Read the full report: https://www.reportlinker.com/p05147399The market size of PVDF...

at 15:54
ROSEMONT, Ill., Oct. 17, 2017 /PRNewswire-USNewswire/ -- The American Academy of Orthopaedic Surgeons (AAOS) today announced plans to create a national family of clinical data registries for a broad range of orthopaedic conditions and procedures. As...

at 15:37
NEW YORK, Oct. 17, 2017 /PRNewswire/ -- The Market for Lab-Developed Test Services and the Market for Instruments and Reagents Sold to LabsRead the full report: https://www.reportlinker.com/p05147466This is a unique report with a unique...

at 15:30
DUBLIN, October 17, 2017 /PRNewswire/ -- The "Breakthroughs in Leveraging Biomarkers for Oncology" report has been added to Research and Markets' offering. Predictive biomarkers are used to provide the best treatment indication with the greater...

at 15:15
DUBLIN, October 17, 2017 /PRNewswire/ -- The "Technology Innovations for Patient Engagement" report has been added to Research and Markets' offering. This research service showcases the different technology innovations in patient engagement and...




News published on 21 june 2017 at 11:22 and distributed by: